TGFB1 and Hepatic fibrosis: Our previous studies found that myeloid-specific disruption of RBPj ameliorates hepatic fibrosis by inhibiting the activation of HSCs to MFs and liver inflammation and reducing the expression of pro-fibrotic factors, including TGF-β and PDGF-β 28.